US76243J1051 - Common Stock
RHYTHM PHARMACEUTICALS INC
NASDAQ:RYTM (12/23/2024, 8:00:01 PM)
After market: 56.04 0 (0%)56.04
-0.08 (-0.14%)
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The company is headquartered in Boston, Massachusetts and currently employs 226 full-time employees. The company went IPO on 2017-10-05. The firm is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS); or Bardet-Biedl syndrome (BBS). The company is evaluating setmelanotide in Phase II and III trials for the treatment of obesity due to variants in one of numerous genes associated with the MC4R pathway.
RHYTHM PHARMACEUTICALS INC
222 Berkeley Street, 12th Floor Boston
Boston MASSACHUSETTS 02116
P: 18572644280
CEO: David P. Meeker
Employees: 226
Website: http://www.rhythmtx.com
BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on...
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on...
Here you can normally see the latest stock twits on RYTM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: